Skip to main content
Log in

Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The effects of midazolam on animal behavior often are evaluated under a chronically food-limited regimen, which is used to implement food-reinforced performance, but the corresponding pharmacokinetics are lacking. The present study investigated the pharmacokinetics of midazolam after IV, SC, IP, and PO administration in food-limited rats. A two-compartment model best described the concentration-time profiles for the four routes of administration. The rate of midazolam absorption was rapid, and peak concentrations were attained in less than 7 min for the three extravascular routes. The mean volume of distribution of the central compartment and clearance were 0.77 l/kg and 2.03 l/h per kg, respectively. Midazolam elimination half-lives for the four routes of administration ranged from 23.1 to 49.5 min, and metabolites could not be detected. The mean absolute bioavailability was route-dependent: 39.3% (SC) 19.2% (IP) and 4.6% (PO). The markedly low oral bioavailability found in food-limited rats contrasted to the value reported for free-feeding rats (45%). Although the IP route yielded the highest maximum concentration on occasion, serum midazolam concentration-time profiles were variable, but did correspond to respective sedative responses. DRL 45-s performance after SC, IP, and PO administration further supported the advisability of using the SC route of administration, as opposed to the IP route, for studying midazolam dose-response relations. The bioavailability values assessed from DRL performance also agree with the measured pharmacokinetic values.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bornemann LD, Min BH, Crews T, Rees MMC, Blumenthal HP, Colburn WA, Patel IH (1985) Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 29:91–95

    Google Scholar 

  • Bourne DWA (1989) Boomer, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Meth Prog Biomed 29:191–195

    Google Scholar 

  • Crevoisier CH, Eckert M, Heizmann P, Thurneysen DJ, Ziegler WH (1981) Relation entre l'effet clinique et la pharmacocinetique du midazolam apres l'administration IV et IM 2eme communication: Aspects pharmacocinetiques. Arzneimittelforschung 31:2211–2215

    Google Scholar 

  • Crevoisier CH, Ziegler WH, Eckert M, Heizmann P (1983) Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 16:51S-61S

    Google Scholar 

  • Guengerich FP (1995) Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr 61:651S-658S

    Google Scholar 

  • Heizmann PM, Eckert M, Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16:43S-49S

    Google Scholar 

  • Heizmann P, Ziegler WH (1981) Excretion and metabolism of14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–2223

    Google Scholar 

  • Igari Y, Sugiyama Y, Sawada Y, Iga T, Hanano M (1982) Tissue distribution of C-diazepam and its metabolites in rats. Drug Metab Dispos 10:676–679

    Google Scholar 

  • Jack ML, Colburn WA, Spirt NM, Bautz G, Zanko M, Horst WD, O'Brien RA (1983) A pharmacokinetic/pharmacodynamic recepto binding model to predict the onset and duration of action of pharmacological activity of the benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 7:629–635

    Google Scholar 

  • Kolars JC, Schmiedlin-Ren P, Dobbins WO, Schuetz J, Wrighton SA, Watkins PB (1992) Hetergeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186–1198

    Google Scholar 

  • Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB (1995) Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J Clin Psychopharmacol 15:259–262

    Google Scholar 

  • Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96

    Google Scholar 

  • Latini R, Bonati M, Castelli D, Garattini S (1978) Dose-dependent kinetics of caffeine in rats. Toxicol Lett 2:267–270

    Google Scholar 

  • Lau CE, Falk J (1991) Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam. Pharmacol Biochem Behav 40:723–731

    Google Scholar 

  • Lau CE, Wang J (1996) Alprazolam, caffeine, and their interaction: relating DRL performance to pharmacokinetics. Psychopharmacology 126:115–124

    Google Scholar 

  • Lau CE, Falk JL, Dolan S, Tang M (1987) Simultaneous determination of flurazepam and five metabolites in serum by HPLC and its application to pharmacokinetic studies in rats. J Chromatogr 423:251–259

    Google Scholar 

  • Lau CE, Falk JL, Tang M (1990) Motor performance decrement by midazolam: antagonism by Ro 15-1788 and CGS 8216. Pharmacol Biochem Behav 36:139–143

    Google Scholar 

  • Lau CE, Ma F, Falk JL (1995) Oral and IP caffeine pharmacokinetics under a chronic food-limitation condition. Pharmacol Biochem Behav 50:245–252

    Google Scholar 

  • Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008–1021

    Google Scholar 

  • Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB (1995) The erythromycin breathtest predicts the clearance of midazolam. Clin Pharmacol Ther 57:16–24

    Google Scholar 

  • Mandema JW, Tukker E, Danhof M (1991) Pharmacokinetic-pharmacodynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102:663–668

    Google Scholar 

  • Owens MJ, Vargas MA, Knight DL, Nemeroff CB (1991) The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther 258:349–356

    Google Scholar 

  • Pier L, Schooner R, Scherschlicht R, Polc P, Sepinwall J, Davidson A, Mohler H, Cumin R, Da Prada M, Burkard WP, Keller HH, Muller RKM, Gerold M, Pier M, Cook L, Haefely W (1981) Pharmacology of midazolam. Arzneimittelforschung 31:2180–2201

    Google Scholar 

  • Sachan DS (1982) Modulation of drug metabolism by food restriction in male rats. Biochem Biophys Res Commun 104:984–989

    Google Scholar 

  • Sethy VH, Francis JW, Elfring G (1987) Onset and duration of action of benzodiazepines as determined by inhibition of (3H)-flunitrazepam binding. Drug Dev Res 10:117–121

    Google Scholar 

  • Tang M, Lau CE, Falk JL (1988) Midazolam and discriminative motor control: chronic administration, withdrawal and modulation by the antagonist Ro 15-1788. J Pharmacol Exp Ther 246:1053–1060

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lau, C.E., Ma, F., Wang, Y. et al. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology 126, 241–248 (1996). https://doi.org/10.1007/BF02246454

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246454

Key words

Navigation